Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus

Br J Dermatol. 2024 Jun 20;191(1):138-140. doi: 10.1093/bjd/ljae141.
No abstract available

Publication types

  • Letter
  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Drug Therapy, Combination* / methods
  • Epidermolysis Bullosa / complications
  • Epidermolysis Bullosa / drug therapy
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy
  • Rituximab* / administration & dosage
  • Rituximab* / therapeutic use
  • Treatment Outcome

Substances

  • Rituximab
  • Antibodies, Monoclonal, Humanized
  • belimumab
  • Immunosuppressive Agents